Frontiers in Oncology (Jan 2021)

DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk

  • Anna Maria Caroleo,
  • Maria Antonietta De Ioris,
  • Luigi Boccuto,
  • Luigi Boccuto,
  • Iside Alessi,
  • Giada Del Baldo,
  • Antonella Cacchione,
  • Emanuele Agolini,
  • Martina Rinelli,
  • Annalisa Serra,
  • Andrea Carai,
  • Angela Mastronuzzi

DOI
https://doi.org/10.3389/fonc.2020.614541
Journal volume & issue
Vol. 10

Abstract

Read online

DICER1 syndrome is a rare genetic condition predisposing to hereditary cancer and caused by variants in the DICER1 gene. The risk to present a neoplasm before the age of 10 years is 5.3 and 31.5% before the age of 60. DICER1 variants have been associated with a syndrome involving familial pleuropulmonary blastoma (PPB), a rare malignant tumor of the lung, which occurs primarily in children under the age of 6 years and represents the most common life-threatening manifestation of DICER1 syndrome. Type I, II, III, and Ir (type I regressed) PPB are reported with a 5-year overall survival ranging from 53 to 100% (for type Ir). DICER1 gene should be screened in all patients with PPB and considered in other tumors mainly in thyroid neoplasms (multinodular goiter, thyroid cancer, adenomas), ovarian tumors (Sertoli-Leydig cell tumor, sarcoma, and gynandroblastoma), and cystic nephroma. A prompt identification of this syndrome is necessary to plan a correct follow-up and screening during lifetime.

Keywords